Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Program Description

Type 2 diabetes (T2D) is a progressive, common condition affecting more than 34 million people and can lead to serious complications, including heart and kidney disease, if not well managed. Current guidelines recommend therapies such as GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and SGLT2 inhibitors, which help improve blood sugar control and reduce cardiovascular and kidney risks. Despite these advances, many people with diabetes are still challenged to achieve their treatment goals. A key factor is therapeutic inertia, or the failure to initiate or intensify therapy in a timely manner when treatment goals are not being met. Awareness that therapeutic inertia can lead to prolonged periods of uncontrolled blood glucose, increasing the risk of complications, is key for pharmacists to identify and support people living with T2D. This program will focus on actionable strategies pharmacists can take when informed by clinical guideline updates. Learners will be guided through interactive patient cases that will highlight evidence from key clinical trials and promote discussion of real-world approaches for using GLP-1 receptor agonists, dual GIP/GLP-1 RAs, and SGLT2 inhibitors. In addition, we will share actionable insights gathered from pharmacist participants across several chapter meeting programs held throughout the United States, offering a broader perspective on common challenges and strategies in T2D management.

Target Audience: Community and health system pharmacist

Type of Activity: Application
Release date: December 23, 2025
Expiration date: December 23, 2026
Learner level: Foundational and intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the clinical burden of uncontrolled type 2 diabetes (T2D) and its relationship with cardiovascular and kidney complications.
• Explore the most current guidelines along with supporting evidence from clinical trials to determine when to initiate or intensify incretin therapies for people living with diabetes.
• Apply pharmacist-led interventions to minimize barriers and prevent therapeutic inertia in T2D.
• Integrate insights on barriers and challenges identified by pharmacists across prior sessions to tailor strategies that increase prescribing of evidence-based incretin therapy.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-421-H01-P. The activity is available for CE credit through December 19, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Medtronic, Tandem Speakers Bureau: Dexcom, Abbott, Insulet, Ascensia, Cequr, Mannkind, Novo Nordisk, Lilly, Cequr

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Susan Cornell, PharmD, CDCES, FAPhA, FADCES

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms